AU2002235129A1 - Treatment of anti-depression drug-induced sexual dysfunction with apomorphine - Google Patents

Treatment of anti-depression drug-induced sexual dysfunction with apomorphine

Info

Publication number
AU2002235129A1
AU2002235129A1 AU2002235129A AU3512902A AU2002235129A1 AU 2002235129 A1 AU2002235129 A1 AU 2002235129A1 AU 2002235129 A AU2002235129 A AU 2002235129A AU 3512902 A AU3512902 A AU 3512902A AU 2002235129 A1 AU2002235129 A1 AU 2002235129A1
Authority
AU
Australia
Prior art keywords
hydrochloride
apomoφhine
patient
administered
apomorphine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002235129A
Other languages
English (en)
Inventor
Renee J. Perdok
Dustin D. Ruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tap Pharmaceuticals Inc
Original Assignee
TAP Holding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TAP Holding Inc filed Critical TAP Holding Inc
Publication of AU2002235129A1 publication Critical patent/AU2002235129A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2002235129A 2000-11-15 2001-11-14 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine Abandoned AU2002235129A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24903100P 2000-11-15 2000-11-15
US60/249,031 2000-11-15
PCT/US2001/043933 WO2002039879A2 (fr) 2000-11-15 2001-11-14 Traitement d'un dysfonctionnement sexuel entraine par une medication antidepressive par apomorphine

Publications (1)

Publication Number Publication Date
AU2002235129A1 true AU2002235129A1 (en) 2002-05-27

Family

ID=22941748

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002235129A Abandoned AU2002235129A1 (en) 2000-11-15 2001-11-14 Treatment of anti-depression drug-induced sexual dysfunction with apomorphine

Country Status (18)

Country Link
US (1) US6528521B2 (fr)
EP (1) EP1341536A4 (fr)
JP (1) JP2004513899A (fr)
KR (1) KR20030077538A (fr)
CN (1) CN1486183A (fr)
AU (1) AU2002235129A1 (fr)
BG (1) BG107874A (fr)
BR (1) BR0111982A (fr)
CA (1) CA2429047A1 (fr)
CZ (1) CZ20031540A3 (fr)
HU (1) HUP0302436A3 (fr)
IL (1) IL155667A0 (fr)
MX (1) MXPA03004288A (fr)
NO (1) NO20032189L (fr)
PL (1) PL361875A1 (fr)
SK (1) SK7422003A3 (fr)
WO (1) WO2002039879A2 (fr)
ZA (1) ZA200303471B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
EP1667972B1 (fr) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereoisomeres de 4-aryloxy-3-hydroxypiperidines
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
CA3115378A1 (fr) 2010-12-16 2012-06-21 Sunovion Pharmaceuticals Inc. Films sublinguaux comprenant de l'apomorphine et une base organique
CN104884064A (zh) 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
WO2016172095A1 (fr) 2015-04-21 2016-10-27 Cynapsus Therapeutics, Inc. Méthodes de traitement de la maladie de parkinson par l'administration d'apomorphine à une muqueuse orale
WO2017168174A1 (fr) 2016-04-02 2017-10-05 N4 Pharma Uk Limited Nouvelles formes pharmaceutiques du sildénafil
MX2020007656A (es) 2018-01-18 2020-09-18 Leukos Biotech S L Forma cristalina de particulas sólidas de cocristal de apomorfina·ácido palmítico.
US11717495B2 (en) * 2020-03-16 2023-08-08 Vella Bioscience, Inc. Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN115671106B (zh) * 2021-07-21 2024-03-19 广州新济药业科技有限公司 吗啡的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
EP0865789B1 (fr) * 1993-03-26 2005-03-16 Franciscus Wilhelmus Henricus Maria Merkus Compositions pharmaceutiques pour une administration intranasale de dihydroergotamine
ATE312609T1 (de) 1994-04-22 2005-12-15 Pentech Pharmaceuticals Inc Sublinguale zusammensetzung enthaltend apomorphine zur diagnose der funktionellen impotenz
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
EP0914097B1 (fr) 1996-03-12 2002-01-16 Alza Corporation Composition et forme galenique contenant un antagoniste des opioides
US5897864A (en) 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
WO1998024442A1 (fr) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des troubles de la sexualite
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
US6399826B1 (en) * 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain

Also Published As

Publication number Publication date
WO2002039879A3 (fr) 2002-07-25
ZA200303471B (en) 2004-08-06
WO2002039879A2 (fr) 2002-05-23
HUP0302436A2 (hu) 2003-11-28
EP1341536A2 (fr) 2003-09-10
BR0111982A (pt) 2003-10-28
US20020115683A1 (en) 2002-08-22
KR20030077538A (ko) 2003-10-01
JP2004513899A (ja) 2004-05-13
PL361875A1 (en) 2004-10-04
CA2429047A1 (fr) 2002-05-23
BG107874A (bg) 2004-01-30
CN1486183A (zh) 2004-03-31
EP1341536A4 (fr) 2007-08-01
SK7422003A3 (en) 2004-01-08
US6528521B2 (en) 2003-03-04
HUP0302436A3 (en) 2004-10-28
CZ20031540A3 (cs) 2004-05-12
MXPA03004288A (es) 2004-09-10
IL155667A0 (en) 2003-11-23
NO20032189L (no) 2003-07-08
NO20032189D0 (no) 2003-05-14

Similar Documents

Publication Publication Date Title
US6528521B2 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US6506765B2 (en) Apomorphine derivatives and methods for their use
KR100719977B1 (ko) 성기능 장애 치료를 위하여 효과 발현이 신속한 선택적 세로토닌 재흡수 억제제를 사용하는 방법
US20060106113A1 (en) Method of delaying ejaculation
WO1996033705A1 (fr) Procede et formulations servant a moduler la reaction sexuelle chez l'homme ou la femme
US20020006933A1 (en) Method for treating sexual dysfunction with apomorphine at specified plasma concentration levels
AU749703B2 (en) Combination therapy for modulating the human sexual response
AU2002252361A1 (en) Method of delaying ejaculation
US20020086876A1 (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application